WHO Recommends Injectable Lenacapavir for HIV Prevention
WHO recommended twice-yearly injectable lenacapavir as an additional HIV pre-exposure prophylaxis option in 2025.
Topics: science and technology, society and culture
Example
What happened: WHO recommended twice-yearly injectable lenacapavir as an additional HIV pre-exposure prophylaxis option in 2025.
Use it for: medical innovation can reduce health inequality only if new treatments are affordable and reach the people at highest risk.
Why it matters: a twice-yearly injection is easier to keep up than a daily pill, which could help people who struggle with daily prevention; but price and supply decide whether it reaches poorer countries.
Limit: A less frequent medicine can improve choice and adherence, but price, supply, stigma, testing, and health-system access remain barriers.
Key facts
- WHO recommended twice-yearly injectable lenacapavir as an additional HIV pre-exposure prophylaxis option in 2025.
How to use this example in a GP essay
Does medical innovation reduce health inequality?
Claim
medical innovation can reduce health inequality only if new treatments are affordable and reach the people at highest risk
How the evidence supports it
a twice-yearly injection is easier to keep up than a daily pill, which could help people who struggle with daily prevention; but price and supply decide whether it reaches poorer countries
Limitation
A less frequent medicine can improve choice and adherence, but price, supply, stigma, testing, and health-system access remain barriers.
Relevance
It gives a current health case for questions on whether innovation reduces or widens inequality.
Limitations
- A less frequent medicine can improve choice and adherence, but price, supply, stigma, testing, and health-system access remain barriers.
Evaluations
science and technology evaluation
Support
Twice-yearly injections remove the need for daily pills, which can improve how consistently people stay protected.
Counterargument
Price, supply and health-system access remain barriers.
Rebuttal
A WHO recommendation helps countries and funders plan procurement, which can bring prices down.
Additional support
WHO recommended it in July 2025 as an additional prevention option, not a replacement.
society and culture evaluation
Support
An injection taken twice a year can be more private than daily pills, reducing stigma for users.
Counterargument
Stigma and testing barriers still keep many people from prevention.
Rebuttal
Better tools work alongside outreach; the injection removes one barrier among several.
Additional support
The case links medical science to social questions of access and stigma.
Sources
- World Health Organization (2025-07-14): WHO recommends injectable lenacapavir for HIV prevention